Integra LifeSciences (NASDAQ:IART), a global medical bionic implant company, disclosed last week that the U.S. Food and Drug Administration successfully completed an inspection of its regenerative medicine facility in Plainsboro, New Jersey. The FDA issued a warning letter to the company after inspecting its Plainsboro facility in the third quarter of 2011. At the conclusion of the recent inspection, the FDA found that the company had addressed the issues raised in the warning letter and previous inspectional observations, and it issued no further inspectional observations.
Integra's stock underperformed the market and its peers due to the FDA warning. Now in the absence of any warning the stock is poised to scale higher. In this article I will focus
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|